Ionis Pharmaceuticals Inc

IONS: XNAS (USA)
View Stock Summary
Morningstar Rating for StocksFair ValueEconomic MoatCapital Allocation
dHLOCK|@M$sLOCK|##x%#b$

Ionis Earnings: Peak Sales Raised for Olezarsen Ahead of Label Expansion; Positive Long-Term Outlook

Ionis posted first‑quarter revenue of $246 million, up 86% year over year. Management raised its peak sales outlook for olezarsen to over $3 billion, from at least $2 billion as announced in January, and increased its 2026 revenue guidance by 9% at the midpoint.

Sponsor Center